Mabylon AG

Mabylon AG, a clinical-stage biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and developability properties. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Human-derived antibodies have superior therapeutic potential compared to antibodies derived from conventional sources, such as humanized animal models or artificial libraries. In the case of allergy, for instance, Mabylon’s antibodies derived from allergic patients target disease-relevant epitopes, expanding the knowledge of novel allergenic epitopes and their role in disease progression. For more information, please visit www.mabylon.com